IP Library Granted Patent US 10,517,960
Granted Patent B2
US 10,517,960 · App. 16/378,481 · Granted Dec 31, 2019

Bifunctional polypeptides

Inventors: Bent Karsten Jakobsen (Abingdon, GB); Annelise Brigitte Vuidepot (Abingdon, GB); Yi Li (Guangzhou, CN)
Assignee: Immunocore Limited
A61K47/6849A61K47/6425C07K14/7051C07K16/2809C07K16/46A61K38/00C07K2317/622C07K2317/73C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,517,960
App. No.
16/378,481
Granted
Dec 31, 2019
Kind
B2
Abstract

A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.

Claims (16)

1. A bifunctional molecule, comprising:

a heterodimeric αβ T-Cell Receptor (αβ TCR), wherein the αβ TCR binds specifically to a given pMHC epitope, and

an immune effector polypeptide,

wherein:

the N-terminus of the α chain of the αβ TCR is linked to the C-terminus of a single chain of an immune effector polypeptide comprising CDRs of an anti-CD3 antibody, and

the bifunctional molecule is capable of binding to the given pMHC epitope and CD3, each on a different cell, and thus simultaneously binding to two different cells.

2. A bifunctional molecule, comprising:

a heterodimeric αβ T-Cell Receptor (αβ TCR), wherein the αβ TCR binds specifically to a given pMHC epitope, and

an immune effector polypeptide,

wherein:

the N-terminus of the β chain of the αβ TCR is linked to the C-terminus of a single chain of an immune effector polypeptide comprising CDRs of an anti-CD3 antibody, and

the bifunctional molecule is capable of binding to the given pMHC epitope and CD3, each on a different cell, and thus simultaneously binding to two different cells.

3. The bifunctional molecule of claim 1 , wherein the immune effector polypeptide is a single chain immunoglobulin (scFv) which specifically binds to CD3.

4. The bifunctional molecule of claim 2 , wherein the immune effector polypeptide is a single chain immunoglobulin (scFv) which specifically binds to CD3.

5. The bifunctional molecule of claim 3 , wherein the single chain immunoglobulin comprises SEQ ID NO: 3.

6. The bifunctional molecule of claim 4 , wherein the single chain immunoglobulin comprises SEQ ID NO: 3.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2025
From: ADAPTIMMUNE LIMITED
To: IMMUNOCORE LIMITED
Reel/Frame 072896/0339 →
RELEASE OF SECURITY INTEREST Recorded Nov 11, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOCORE LIMITED
Reel/Frame 069197/0672 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2022
From: OXFORD FINANCE LUXEMBOURG S.À R.L
To: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
Reel/Frame 061916/0493 →
PATENT SECURITY AGREEMENT Recorded Nov 8, 2022
From: IMMUNOCORE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061899/0866 →
SECURITY INTEREST Recorded Nov 6, 2020
From: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
To: OXFORD FINANCE LUXEMBOURG S.À R.L., REGISTERED WITH THE LUXEMBOURG COMMERCIAL REGISTER UNDER NUMBER B243395, ACTING IN RESPECT OF ITS COMPARTMENT 1
Reel/Frame 054344/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: LI, YI; JAKOBSEN, BENT KARSTEN; VUIDEPOT, ANNELISE BRIGITTE
To: IMMUNOCORE LIMITED
Reel/Frame 049756/0895 →
Cited By (6)
US 12,577,321 US 12,600,795 US 12,616,756 US 12,624,097 US 12,649,790 US 12,673,991